{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:15:27Z","timestamp":1761862527106},"reference-count":42,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2006,3,31]],"date-time":"2006-03-31T00:00:00Z","timestamp":1143763200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Science"],"published-print":{"date-parts":[[2006,6]]},"abstract":"<jats:p>Lung cancer is one of the major causes of death in many countries because of high rates of smoking, especially in Asian countries. Lung cancer is divided into two major categories based on their biological characteristics and the selection of treatment methods: non\u2010small cell lung cancer (NSCLC; 85%) and small cell lung cancer (15%). Early detection and complete resection are very important in NSCLC, but the cure rate is not very high, except in stage 1A disease. It is extremely important to understand the biology of lung cancer and to introduce more effective treatments in order to improve the survival of NSCLC patients. Numerous clinical trials involving lung cancer patients have led to \u2018state\u2010of\u2010the\u2010art\u2019 treatments for each stage of the disease. Progress in chemotherapy and molecular target based therapy have altered the standard therapy for NSCLC. (<jats:italic>Cancer sci<\/jats:italic> 2006; 97)<\/jats:p>","DOI":"10.1111\/j.1349-7006.2006.00198.x","type":"journal-article","created":{"date-parts":[[2006,3,31]],"date-time":"2006-03-31T09:18:23Z","timestamp":1143796703000},"page":"448-452","source":"Crossref","is-referenced-by-count":12,"title":["Recent trends in the treatment of advanced lung cancer"],"prefix":"10.1111","volume":"97","author":[{"given":"Nagahiro","family":"Saijo","sequence":"first","affiliation":[]}],"member":"311","published-online":{"date-parts":[[2006,3,31]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011954"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.13.3210"},{"key":"e_1_2_6_4_2","article-title":"Paclitaxel and gemcitabine vs carboplatin and gemcitabine, a multicenter, phase III randomized trial in patients with advanced inoperable non\u2010small cell lung cancer","volume":"23","author":"Kosmidis PA","year":"2005","journal-title":"Proc ASCO"},{"key":"e_1_2_6_5_2","first-page":"9097","article-title":"Paclitaxel\/carboplatin (PC) vs PC + tirapazamine in advanced NSCLC: A phase III SWOG trial S0003","volume":"20","author":"Williamson SK","year":"2003","journal-title":"J Clin Oncol"},{"key":"e_1_2_6_6_2","article-title":"Japan\u2010SWOG common arm analysis of paclitaxel\/carboplatin in advanced stage non\u2010small cell lung cancer (NSCLC): a model for prospective comparison of co\u2010operative group trial","volume":"22","author":"Gandara DR","year":"2004","journal-title":"Proc ASCO"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.02.108"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.09.075"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh031"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.10.112"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.03.038"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.10.038"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.08.001"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.07.215"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67625-8"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050753"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.840"},{"key":"e_1_2_6_18_2","article-title":"Results of a phase III trial of erlotinib (OSI\u2010774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced NSCLC","volume":"22","author":"Gatzemeier U","year":"2004","journal-title":"TALENT Trial Proc ASCO"},{"key":"e_1_2_6_19_2","article-title":"Preliminary results of S0023: A randomized phase III trial of cisplatin\/etoposide\/TRT followed by consolidation docetaxelthan maintenance therapy with gefitinib or placebo in patients with locally advanced inoperable stage III NSCLC","volume":"41","author":"Kelly K","year":"2005","journal-title":"Proceedings ASCO"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-2360"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040938"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1099314"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.388"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.97.008"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncponc0341"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dji055"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-2818"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.00.992"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0020073"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa044238"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.08.043"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.7078"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050736"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dji112"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.09.111"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.11.069"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.2823"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dji127"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-5002(05)80978-X"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.0793"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0603-685"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.11.022"},{"key":"e_1_2_6_43_2","first-page":"2s","article-title":"Randomized phase II\/III trial of paclitaxel plus carboplatin with or without bevacizumab in patients with advanced non\u2010squamous NSCLC: An Eastern Cooperative Oncology Group Trial\u2010E4599","volume":"23","author":"Sandler AB","year":"2005","journal-title":"Proc ASCO"}],"container-title":["Cancer Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1349-7006.2006.00198.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1349-7006.2006.00198.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T08:10:41Z","timestamp":1697184641000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1349-7006.2006.00198.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,3,31]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2006,6]]}},"alternative-id":["10.1111\/j.1349-7006.2006.00198.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1349-7006.2006.00198.x","archive":["Portico"],"relation":{},"ISSN":["1347-9032","1349-7006"],"issn-type":[{"value":"1347-9032","type":"print"},{"value":"1349-7006","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,3,31]]}}}